Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

XAIR

Beyond Air Inc

Sep 20 • 04:00PM ET

0.4000

Dollar change +0.0179
Percentage change 4.68	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-1.63	Insider Own	19.06%	Shs Outstand	45.90M	Perf Week	-4.43%
Market Cap	18.61M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	3.37%	Shs Float	37.65M	Perf Month	-13.51%
Income	-58.35M	PEG	-	EPS next Q	-0.28	Inst Own	25.95%	Short Float	1.59%	Perf Quarter	-67.74%
Sales	1.78M	P/S	10.45	EPS this Y	44.07%	Inst Trans	10.19%	Short Ratio	0.73	Perf Half Y	-75.46%
Book/sh	0.35	P/B	1.14	EPS next Y	29.86%	ROA	-97.62%	Short Interest	0.60M	Perf Year	-85.87%
Cash/sh	0.46	P/C	0.86	EPS next 5Y	-	ROE	-226.22%	52W Range	0.36 - 3.08	Perf YTD	-79.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.68%	ROI	-177.53%	52W High	-87.01%	Beta	-0.11
Dividend TTM	-	Quick Ratio	2.42	Sales past 5Y	-43.84%	Gross Margin	-125.10%	52W Low	12.36%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	2.63	EPS Y/Y TTM	15.47%	Oper. Margin	-3405.05%	RSI (14)	42.55	Volatility	7.60% 8.24%
Employees	107	Debt/Eq	1.10	Sales Y/Y TTM	2922.03%	Profit Margin	-3272.46%	Recom	1.40	Target Price	3.75
Option/Short	Yes / Yes	LT Debt/Eq	1.04	EPS Q/Q	40.81%	Payout	-	Rel Volume	0.41	Prev Close	0.38
Sales Surprise	-14.41%	EPS Surprise	14.80%	Sales Q/Q	1057.63%	Earnings	Aug 06 AMC	Avg Volume	815.03K	Price	0.40
SMA20	-4.21%	SMA50	-16.48%	SMA200	-67.22%	Trades		Volume	335,867	Change	4.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Downgrade	BTIG Research	Buy → Neutral
Jul-28-23	Initiated	Piper Sandler	Overweight	$10
Jun-15-23	Initiated	BTIG Research	Buy	$15
Apr-28-21	Initiated	Truist	Buy	$12
Oct-22-19	Initiated	Oppenheimer	Outperform	$9

Aug-06-24 04:05PM	Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -17.38%
Jul-31-24 04:15PM	Beyond Air Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia (GlobeNewswire) -5.16%
Jul-23-24 04:05PM	Beyond Air to Report First Fiscal Quarter 2025 Financial Results on August 6 (GlobeNewswire) +5.29%
Jul-16-24 04:05PM	Beyond Air To Participate in the BTIG Virtual Biotechnology Conference 2024 (GlobeNewswire)
Jul-10-24 09:55AM	Beyond Air (XAIR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +5.59%
08:01AM	Loading…
Jun-26-24 08:01AM	Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-25-24 10:31AM	Jefferies Just Raised Its Price Target on Nvidia (NVDA) Stock (InvestorPlace) -51.54%
08:28AM	Why Is Beyond Air (XAIR) Stock Down 22% Today? (InvestorPlace)
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-24-24 08:53PM	XAIR Stock Earnings: Beyond Air Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +8.06%
05:25PM	Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Beyond Air Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-13-24 04:05PM	Beyond Air Appoints David Webster as Chief Commercial Officer (GlobeNewswire)
Jun-03-24 07:00AM	Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) (GlobeNewswire) -8.59%
May-23-24 04:09PM	Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -9.50%
07:00AM	Loading…
May-01-24 07:00AM	Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
Mar-21-24 12:00PM	Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +5.84%
Mar-20-24 09:00AM	Beyond Air Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Feb-13-24 08:51AM	Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript (Insider Monkey) -17.67%
Feb-12-24 04:05PM	Beyond Air Reports Financial Results for Third Quarter of Fiscal Year 2024 (GlobeNewswire) +14.97%
Jan-18-24 08:00AM	Beyond Air Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -5.02%
Dec-27-23 07:30AM	Beyond Cancer Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors (GlobeNewswire)
Dec-21-23 01:40AM	Insider Buying: CEO Steven Lisi Acquires 77,775 Shares of Beyond Air Inc (GuruFocus.com) +12.04%
Nov-15-23 04:05PM	Beyond Air To Participate in the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +23.57% -8.96%
Nov-14-23 10:00AM	Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Call Transcript (Insider Monkey) -31.03%
Nov-13-23 04:05PM	Beyond Air Reports Financial Results for Second Quarter of Fiscal Year 2024 (GlobeNewswire)
Nov-03-23 12:00PM	Beyond Cancer Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire) -6.91%
Oct-19-23 04:05PM	Beyond Air Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire)
Oct-17-23 04:05PM	Beyond Air To Participate in the Truist Securities BioPharma Symposium (GlobeNewswire) +8.48% -6.17%
07:30AM	Beyond Cancer Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice (GlobeNewswire)
07:30AM	Loading…
Oct-16-23 07:30AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
07:00AM	Beyond Air Receives Innovative Technology Contract from Vizient for LungFit PH (GlobeNewswire)
Oct-04-23 07:30AM	Beyond Cancer Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-23 04:05PM	Beyond Air To Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -7.79%
Sep-27-23 09:00AM	Beyond Cancer to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting (GlobeNewswire)
Sep-18-23 04:05PM	Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder (GlobeNewswire) -7.95% +6.83%
Sep-07-23 07:30AM	Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region (GlobeNewswire)
Sep-06-23 07:00AM	Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-10-23 04:05PM	Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024 (GlobeNewswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +13.35%
Aug-07-23 04:05PM	Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD) (GlobeNewswire)
Aug-01-23 04:05PM	Beyond Air® To Participate in BTIGs 2023 Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-23 10:13AM	Block upgraded, Southwest downgraded: Wall Street's top analyst calls (The Fly) +7.12%
Jul-24-23 04:05PM	Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast (GlobeNewswire) -6.11% -5.42%
Jun-22-23 04:05PM	Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023 (GlobeNewswire) -18.84%
Jun-15-23 04:10PM	Beyond Air® Secures up to $40 Million Debt Financing (GlobeNewswire)
04:05PM	Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem (GlobeNewswire)
Jun-09-23 06:34AM	Daily Vickers Top Insider Picks for 06/09/2023 (Argus Research)
Jun-08-23 06:43AM	Daily Vickers Top Insider Picks for 06/08/2023 (Argus Research)
Jun-07-23 08:25AM	Daily Vickers Top Insider Picks for 06/07/2023 (Argus Research)
Jun-06-23 06:34AM	Daily Vickers Top Insider Picks for 06/06/2023 (Argus Research)
Jun-05-23 06:44AM	Daily Vickers Top Insider Picks for 06/05/2023 (Argus Research)
Jun-02-23 06:56AM	Daily Vickers Top Insider Picks for 06/02/2023 (Argus Research)
Jun-01-23 06:29AM	Daily Vickers Top Insider Picks for 06/01/2023 (Argus Research)
May-31-23 06:40AM	Daily Vickers Top Insider Picks for 05/31/2023 (Argus Research)
May-30-23 06:50AM	Daily Vickers Top Insider Picks for 05/30/2023 (Argus Research)
May-26-23 06:59AM	Daily Vickers Top Insider Picks for 05/26/2023 (Argus Research)
May-25-23 06:38AM	Daily Vickers Top Insider Picks for 05/25/2023 (Argus Research)
May-24-23 06:43AM	Daily Vickers Top Insider Picks for 05/24/2023 (Argus Research)
May-23-23 06:33AM	Daily Vickers Top Insider Picks for 05/23/2023 (Argus Research)
May-22-23 07:49AM	Daily Vickers Top Insider Picks for 05/22/2023 (Argus Research)
May-19-23 07:03AM	Daily Vickers Top Insider Picks for 05/19/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Insider Picks for 05/18/2023 (Argus Research)
May-17-23 06:35AM	Daily Vickers Top Insider Picks for 05/17/2023 (Argus Research)
May-16-23 04:05PM	Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Apr-19-23 09:00AM	Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting (GlobeNewswire)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research)
Mar-23-23 04:05PM	Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer (GlobeNewswire) -5.84%
Mar-14-23 04:35PM	Beyond Cancer to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting (GlobeNewswire) +6.59%
Mar-10-23 07:04AM	Daily Vickers Top Buyers & Sellers for 03/10/2023 (Argus Research)
Feb-22-23 07:00AM	Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023 (GlobeNewswire)
Feb-09-23 04:05PM	Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023 (GlobeNewswire) -6.21% -7.83%
Jan-30-23 07:00AM	Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer (GlobeNewswire)
Jan-24-23 04:05PM	Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board (GlobeNewswire)
Jan-17-23 04:05PM	Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Dec-13-22 09:25AM	Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases (GlobeNewswire) +9.26%
Nov-17-22 04:05PM	Beyond Air® To Participate in Pipers 34th Annual Healthcare Conference (GlobeNewswire) -6.08%
Nov-10-22 09:00AM	Beyond Cancer Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (GlobeNewswire)
Nov-08-22 04:05PM	Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023 (GlobeNewswire) -16.87%
Oct-24-22 07:30AM	Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022 (GlobeNewswire)
Oct-20-22 04:05PM	Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire) +7.55%
Oct-17-22 04:05PM	Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022 (GlobeNewswire) +29.85%
Oct-05-22 08:00AM	Beyond Cancer to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting (GlobeNewswire)
Oct-03-22 07:30AM	Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis (GlobeNewswire)
Sep-16-22 04:05PM	Beyond Air® To Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-23-22 08:00AM	Beyond Air® Affiliate Beyond Cancer Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov) (GlobeNewswire) +10.12%
Aug-11-22 04:05PM	Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023 (GlobeNewswire) +8.07%
Jul-27-22 04:05PM	Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast (GlobeNewswire)
Jun-28-22 04:10PM	Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022 (GlobeNewswire) -7.81% +8.13%
04:05PM	Beyond Airs LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure (GlobeNewswire)
Jun-14-22 04:30PM	Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th (GlobeNewswire) +9.84%
Jun-01-22 07:00AM	Beyond Cancer Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer (GlobeNewswire)
May-17-22 04:05PM	Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022 (GlobeNewswire) +7.84%
07:00AM	Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer (GlobeNewswire)
May-16-22 07:05AM	Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast (GlobeNewswire)
May-06-22 06:29AM	Loss-Making Beyond Air, Inc. (NASDAQ:XAIR) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Apr-25-22 04:05PM	Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022 (GlobeNewswire) +12.02%
07:00AM	Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022 (GlobeNewswire)
Apr-18-22 07:00AM	Beyond Air® to Participate in Three Upcoming Medical Conferences (GlobeNewswire)
Apr-11-22 07:00AM	Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect (GlobeNewswire) -7.95%

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Avniel Amir	Officer	Aug 22 '24	Proposed Sale	0.46	180,415	83,442		Aug 22 10:13 AM
Lisi Steven A.	CEO and Chairman of the Board	Aug 15 '24	Buy	0.37	50,000	18,340	1,772,785	Aug 19 06:06 AM
Lucera Erick	Director	Aug 14 '24	Buy	0.40	39,266	15,565	43,608	Aug 15 05:09 PM
Carey Robert	Director	Aug 14 '24	Buy	0.40	100,000	39,680	3,076,864	Aug 15 05:09 PM
Lisi Steven A.	CEO and Chairman of the Board	Aug 14 '24	Buy	0.39	100,000	38,640	1,722,785	Aug 15 05:09 PM
Avniel Amir	Chief Business Officer	Dec 28 '23	Sale	2.05	13,733	28,217	0	Dec 29 04:23 PM
Avniel Amir	Chief Business Officer	Dec 28 '23	Sale	2.06	11,267	23,234	685,760	Dec 29 04:23 PM
Myers Jeff Lynn	Chief Medical Officer	Dec 27 '23	Sale	2.21	3,423	7,579	46,577	Dec 29 04:15 PM
Lisi Steven A.	CEO and Chairman of the Board	Dec 18 '23	Buy	1.63	77,775	126,797	1,536,471	Dec 19 05:15 PM
Carey Robert	Director	Dec 18 '23	Buy	1.64	1,200,000	1,962,000	2,374,454	Dec 19 05:13 PM
Gaul Michael A.	Chief Operating Officer	Nov 16 '23	Buy	1.77	10,000	17,700	88,150	Nov 17 04:15 PM

Open in Screener

EDIT

Editas Medicine Inc

Sep 20 • 04:00PM ET

3.77

Dollar change -0.14
Percentage change -3.58	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

EDIT Editas Medicine Inc daily Stock Chart

Held by: VTI XBI IWM VXF VB IWN IBB VBK DFAT SCHA

Index	RUT	P/E	-	EPS (ttm)	-2.36	Insider Own	0.94%	Shs Outstand	81.77M	Perf Week	-4.56%
Market Cap	310.95M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	-1.35%	Shs Float	81.70M	Perf Month	-7.60%
Income	-193.45M	PEG	-	EPS next Q	-0.78	Inst Own	69.52%	Short Float	22.04%	Perf Quarter	-26.22%
Sales	67.03M	P/S	4.64	EPS this Y	-44.10%	Inst Trans	2.32%	Short Ratio	9.74	Perf Half Y	-51.85%
Book/sh	2.81	P/B	1.34	EPS next Y	5.67%	ROA	-41.75%	Short Interest	18.01M	Perf Year	-52.58%
Cash/sh	3.38	P/C	1.11	EPS next 5Y	1.70%	ROE	-61.23%	52W Range	3.40 - 11.69	Perf YTD	-62.78%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.88%	ROI	-76.61%	52W High	-67.75%	Beta	1.99
Dividend TTM	-	Quick Ratio	3.85	Sales past 5Y	101.57%	Gross Margin	91.33%	52W Low	10.88%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	3.85	EPS Y/Y TTM	20.53%	Oper. Margin	-317.78%	RSI (14)	44.30	Volatility	5.82% 5.59%
Employees	265	Debt/Eq	0.17	Sales Y/Y TTM	247.03%	Profit Margin	-288.59%	Recom	2.05	Target Price	13.80
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-45.51%	Payout	-	Rel Volume	3.12	Prev Close	3.91
Sales Surprise	-89.27%	EPS Surprise	-16.48%	Sales Q/Q	-82.23%	Earnings	Aug 07 BMO	Avg Volume	1.85M	Price	3.77
SMA20	0.75%	SMA50	-14.58%	SMA200	-42.75%	Trades		Volume	5,769,271	Change	-3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral	$25 → $13
Sep-29-22	Initiated	BofA Securities	Neutral	$18
Oct-19-21	Initiated	SVB Leerink	Mkt Perform	$41
Sep-24-21	Initiated	Stifel	Hold	$65
Sep-10-21	Upgrade	Oppenheimer	Perform → Outperform	$42 → $80
Aug-09-21	Upgrade	Truist	Hold → Buy	$45 → $80
Aug-05-21	Upgrade	Evercore ISI	Underperform → Outperform	$20 → $60
Jun-04-21	Resumed	Robert W. Baird	Outperform	$44
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$40

Show Previous Ratings

Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)
03:39AM	Q2 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:05AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -12.18%
07:07AM	Loading…
07:07AM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Second Quarter 2024 Results and Business Updates (GlobeNewswire)
Jul-31-24 07:00AM	Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-17-24 11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace) +5.01%
Jun-29-24 08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 09:04AM	What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential? (Insider Monkey)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
04:36PM	Loading…
04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-25-24 08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-17-24 08:13AM	Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies (Zacks)
Jun-14-24 03:01AM	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.83%
03:00AM	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire)
Jun-07-24 11:30AM	Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-22-24 07:05PM	EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (GuruFocus.com) +9.26%
May-14-24 07:01PM	Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (GuruFocus.com) +5.63%
04:27PM	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing (MT Newswires)
10:00AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June (GlobeNewswire)
May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Loading…
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-22-24 04:31PM	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? (Zacks)
Mar-07-24 03:31AM	1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. (Motley Fool)
Mar-05-24 11:52PM	Insider Sells Shares of Editas Medicine Inc (EDIT) (GuruFocus.com) -7.86%
Mar-04-24 10:30AM	1 Beaten-Down Stock With 55% Upside, According to Wall Street (Motley Fool) -5.79%
Mar-02-24 09:49PM	Why Editas Medicine Stock Soared as Much as 42% Higher This Week (Motley Fool)
Feb-29-24 11:26AM	Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.12%
08:42AM	Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up (Zacks)
Feb-28-24 11:15PM	Q4 2023 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) +24.94%
08:10AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials (GuruFocus.com)
07:08AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates (GlobeNewswire)
Feb-21-24 07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Feb-19-24 09:55AM	Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade (Zacks)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 12:00PM	What Makes Editas (EDIT) a New Buy Stock (Zacks)
Jan-31-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-21-24 09:37AM	Could Editas Medicine Become the Next CRISPR Therapeutics? (Motley Fool)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-15-24 05:19AM	Down 88%, Could Editas Medicine Be a Good Investment Now? (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 08:15AM	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool)
Jan-03-24 07:00AM	Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.11%
Jan-02-24 10:15AM	Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why (Zacks)
Dec-23-23 08:02AM	Editas Just Caught a Break Thanks to Vertex Pharmaceuticals (Motley Fool)
Dec-14-23 08:32AM	Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6% (Zacks)
06:30AM	Editas cashes in on CRISPR patent with Vertex deal (BioPharma Dive)
Dec-13-23 05:12PM	S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the Fed (Investopedia) +5.69%
04:06PM	Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal (Investopedia)
12:30PM	Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss (Investopedia)
09:00AM	Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9 (GlobeNewswire)
Dec-11-23 01:22PM	ASH23: Pharma branding, Editas high bar and clinical trial diversity (BioPharma Dive) -5.71%
12:00PM	Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Dec-10-23 11:59AM	12 Best Genomics Stocks To Buy Now (Insider Monkey)
Dec-05-23 07:00AM	1 Promising Stock Down 66% That Could Skyrocket in 2024 (Motley Fool)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
Nov-22-23 06:30AM	Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year (InvestorPlace)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +10.84% -6.64%
05:36AM	2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street (Motley Fool)
Nov-16-23 03:25PM	3 Long-Term Growth Stocks Analysts Are Bullish On (InvestorPlace)
Nov-09-23 03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace) -6.31%
Nov-06-23 09:00AM	Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
Nov-05-23 05:51PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:45AM	Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +18.21%
08:34AM	Editas Medicine Inc (EDIT) Q3 2023 Earnings: Net Loss Narrows to $45. ... (GuruFocus.com)
07:17AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Third Quarter 2023 Results and Business Updates (GlobeNewswire)
Nov-02-23 09:12AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar (GlobeNewswire)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
Oct-27-23 07:00AM	Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly) +5.12%
01:53AM	The Trade Desk cleans up; DraftKings 'stronger than ever': 5 big analyst picks (Investing.com)
Oct-18-23 11:05AM	3 Gene Editing Stocks to Generate Super-Charged Gains (InvestorPlace)
09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool)
Oct-17-23 11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks) -6.20%

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Sep 04 '24	Sale	3.42	518	1,774	133,895	Sep 06 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 04 '24	Sale	3.42	1,555	5,325	313,724	Sep 06 04:18 PM
O'Neill Gilmore Neil	Officer	Sep 03 '24	Proposed Sale	3.92	3,000	11,760		Aug 29 04:19 PM
Mei Baisong	Officer	Sep 03 '24	Proposed Sale	3.92	1,000	3,920		Aug 29 04:17 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 25 '24	Sale	5.42	11,886	64,370	73,136	Jul 26 05:02 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jul 19 '24	Sale	5.21	6,619	34,456	134,413	Jul 22 05:01 PM
O'Neill Gilmore Neil	CEO	Jun 04 '24	Sale	5.50	12,191	66,997	315,279	Jun 06 04:17 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	5.50	511	2,808	141,032	Jun 06 04:16 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	May 20 '24	Sale	5.61	22,337	125,404	116,829	May 22 04:30 PM
Hopfield Jessica	Director	May 13 '24	Buy	5.64	45,000	253,868	67,700	May 14 04:17 PM
O'Neill Gilmore Neil	CEO	Mar 05 '24	Sale	9.42	77,824	732,884	327,470	Mar 05 08:00 PM
Mei Baisong	SVP, CHIEF MEDICAL OFFICER	Mar 04 '24	Sale	9.42	20,327	191,425	141,543	Mar 05 07:54 PM
Eaton Bruce	EVP, CBO AND CTO	Dec 05 '23	Sale	10.90	103	1,122	74,791	Dec 07 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 14 '23	Sale	8.21	695	5,706	74,894	Nov 16 04:30 PM
Eaton Bruce	EVP, CBO AND CTO	Nov 07 '23	Sale	8.40	139	1,168	75,589	Nov 09 04:31 PM

XAIR

Beyond Air Inc

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience